SCYNEXIS Inc

General ticker "SCYX" information:

  • Sector: Health Care
  • Industry: Pharmaceuticals
  • Capitalization: $57.9M

SCYNEXIS Inc does not follow the US Stock Market performance with the rate: -13.4%.

Estimated limits based on current volatility of 4.1%: low 0.96$, high 1.04$

Factors to consider:

  • Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.07$, 2.71$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.43$, 3.29$]

Financial Metrics affecting the SCYX estimates:

  • Positive: 0.93 < Non-GAAP EPS, $ of 1.78
  • Positive: Operating cash flow per share per price, % of 73.29 > 12.76
  • Positive: Operating profit margin, % of 51.85 > 19.51
  • Negative: Industry earnings per price (median), % of -15.01 <= 1.31
  • Positive: Interest expense per share, $ of 0.07 <= 0.14
  • Positive: -0.96 < Investing cash flow per share, $ of -0.73

Similar symbols

Short-term SCYX quotes

Long-term SCYX plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $13.16MM $5.09MM $140.14MM
Operating Expenses $74.00MM $90.85MM $67.47MM
Operating Income $-60.84MM $-85.76MM $72.67MM
Non-Operating Income $24.88MM $18.25MM $-5.49MM
Interest Expense $2.66MM $5.20MM $3.13MM
R&D Expense $23.77MM $27.26MM $30.93MM
Income(Loss) $-35.95MM $-67.51MM $67.18MM
Taxes $-3.09MM $-4.70MM $0.14MM
Profit(Loss) $-32.87MM $-62.81MM $67.04MM
Stockholders Equity $41.26MM $3.23MM $72.96MM
Inventory $0.46MM $0.90MM $0.00MM
Assets $119.84MM $87.81MM $128.41MM
Operating Cash Flow $-54.56MM $-79.88MM $60.16MM
Capital expenditure $1.17MM $0.01MM $0.00MM
Investing Cash Flow $-1.17MM $-27.39MM $-34.88MM
Financing Cash Flow $67.12MM $48.60MM $-36.72MM
Earnings Per Share* $-1.25 $-1.47 $1.40

* EPS are Split Adjusted, recent splits may be reflected with a delay.